RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $379
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $347 to $379.
December 14, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains a 'Sector Perform' rating on Vertex Pharmaceuticals and raises the price target to $379.
The increase in price target by RBC Capital suggests a positive outlook on Vertex Pharmaceuticals' stock value in the short term. The 'Sector Perform' rating indicates that the analyst believes the stock will perform in line with the sector, but the raised target may lead to increased investor confidence and a potential uptick in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100